Skip to main content
Clinical Trials/EUCTR2017-001467-20-SE
EUCTR2017-001467-20-SEActive, not recruitingPhase 1

Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-Oncology Breast Cancer Study. - COBC

Dept. of Oncology, Karolinska university hospital0 sitesStarted: June 22, 2017Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • Women with newly diagnosed breast cancer who are eligible to receive neo-adjuvant or adjuvant chemotherapy, with or without trastuzumab, according to the guidelines for breast cancer.
  • Written informed consent must be given.
  • The participants can be included in other non-competing ongoing trilas.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 250
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

Exclusion Criteria

  • A history of heart disease; ischemic heart disease, arrhythmias, heart failure, and valve diseases.
  • Previously received oncological treatment for any malignancy.
  • Other disease or conditions that complicates or precludes the patient from following the study protocol.
  • Patients in child-bearing age without adequate contraception.

Investigators

Sponsor
Dept. of Oncology, Karolinska university hospital

Similar Trials